This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SLC6A3 · Western blot design guide
SLC6A3 Western Blot Planning Guide
Plan a SLC6A3 Western blot around the catalog-observed 68.5 kDa band, image-backed A00369-3 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
SLC6A3 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 68.5 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Substantia nigra | |
| Negative control | Adrenal gland |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 68.5 kDa |
| ⓘ | Localization | Cell membrane / Cell projection, neuron projection |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated SLC6A3 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Caudate |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A00369-3 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected SLC6A3 Western Blot Band Size?
Use the product-observed 68.5 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 68.5 kDa | Matches the authoritative product WB observation. |
| 68.5 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected SLC6A3 appearancePlan around 68.5 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 68.5 kDa; use this as the primary experimental expectation. |
| Calculated mass | 68.5 kDa from UniProt Q01959; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A00369-3. |
| Situation | Likely cause | Next action |
|---|---|---|
| 68.5 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing SLC6A3 band
A00369-3 · SLC6A3
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for SLC6A3 Western blot
🧪Use Substantia nigra as the first positive-control candidate and Adrenal gland as the HPA Not detected negative candidate.
Positive control: Substantia nigra (High)
Negative control: Adrenal gland (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for SLC6A3
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Section 3
Advanced SLC6A3 Western Blot Tips
Deeper troubleshooting and optimisation questions for SLC6A3, answered from its protein features.
Which band should guide the blot?
Use 68.5 kDa, the observation attached to the authoritative A00369-3 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 68.5 kDa expectation.
Which positive control should I start with?
Start with Substantia nigra, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adrenal gland as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for SLC6A3 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A00369-3 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
SLC6A3 Western Blot Reagents
Human-reactive SLC6A3 Western blot reagents with authoritative product imagery.
Real WB data
Anti-Dopamine Transporter/SLC6A3 Antibody Picoband®
Cat # A00369-3
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q01959
- Human Protein Atlas — SLC6A3
- A00369-3 product record
- PMC12514767 — Solute carrier family 6 member 3 promotes the development of clear cell renal cell carcinoma by enhancing glycolysis and inhibiting ferroptosis (CytoJournal, 2025)
- PMC4736613 — Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma (Molecular cancer, 2016)
- PMC8986433 — Screening and Validation of a Carvacrol-Targeting Viability-Regulating Protein, SLC6A3, in Liver Hepatocellular Carcinoma (Disease markers, 2022)
